Skip to main content

Invokana (Canagliflozin) & Renal Cell Carcinoma

Basic Details
Status
Ongoing
Last Updated
Thursday, July 6, 2023
Original Posting Date
Health Outcome(s)
renal cell carcinoma
Purpose
Drug and Outcome Analysis
Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
Yes
Result(s) (1)
Renal Cell Carcinoma Following Canagliflozin Use in Patients with Type 2 Diabetes: A Descriptive Analysis
Regulatory Link(s) (1)
FDA Approval Package Materials
Related Publication(s) and/or Presentation(s) (1)
Presentation: Use of Glucagon-Like Peptide-1 Receptor Agonists in the U.S. Food and Drug Administration’s Sentinel System